MicroRNAs as Potential Biomarkers -- for Lung Cancer Diagnosis and Identification of Tumor Origin in Patients With Cancer of Unknown Primary
(CUP) MicroRNAs Objectively Identify Cancer Types With High Sensitivity and Specificity and Could Revolutionize Diagnosis and Treatment of Cancer
Results of microRNA Signature to Identify Tissue Origin Demonstrate
Accuracy Exceeding 90% and Specificity of 99%
REHOVOT, Israel and JERSEY CITY, New Jersey, May 16 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, today announced that it will present multiple posters at the upcoming ASCO annual meeting in Chicago. The company also has three publication only abstracts available on ASCO's website. The event will take place from May 30 to June 3 at the McCormick Place, Chicago, Illinois.
1. "MicroRNA signature identifies tissue origin of primary and metastatic tumors"; Tuesday, June 03, 8:00AM - 12:00PM; Hall S102a, abstract # 11028.
Each year approximately 70,000 patients in the United States are diagnosed with cancer of unknown primary (CUP). Accurately identifying the origin of a metastasis can be critical in guiding treatment decisions. Rosetta Genomics' scientists have designed a classifier which assigns a primary site to a cancer sample based on the microRNA expression in the sample. The overall sensitivity of this classifier is approximately 85%, with two-thirds of the samples being classified with high-confidence, reaching accuracy exceeding 90% and specificity of 99%.
2. "Differential microRNA expression in pleural mesothelioma: Implications for early detection and prognostication"; Tuesday, June 03; 8:00AM - 12:00PM; Hall S102a; abstract # 11027. Malignant mesothelioma (MM) is an asbestos induced pleural neoplasm with a median survival (MS) of 12 months, and relatively little is known about the molecular events that lead to the development of this highly aggressive disease. Using Rosetta Genomics' unique microRNA platform, Dr. Harvey Pass, NYU School of Medicine, examines whether there are distinct mir profiles between MM and normal mesothelium, and whether mirs are associated with demographic/prognostic features in MM patients.
3. "MicroRNAs as powerful diagnostic tools for the differential diagnosis of lung tumors"; Sunday, June 01; 8:00AM - 12:00PM; Hall S A1; abstract # 11112. Lung cancer is a heterogeneous disease with many histological subtypes, further complicated by the frequent occurrence of lung metastases from various tumor origins. Therefore, determining the correct diagnosis of any lung tumor often poses a difficult diagnostic challenge that may have very significant therapeutic implications. This poster will detail the use of microRNAs for differentiating between different primary lung tumors and metastases to the lung.
4. "MicroRNA expression profile identifies origin of tumors in the liver"; Tuesday, June 03; 8:00AM - 12:00PM; Hall S102a; abstract # 11026. The distinction of liver metastasis from hepatocellular carcinoma (HCC) and determining its tissue origin is a frequent problem in oncology, especially since liver metastases, and particularly adenocarcinoma, may mimic the morphology and immunoexpression of hepatocellular carcinoma. Such distinction has significant therapeutic and prognostic implications. In the present study, Rosetta Genomics and collaborators use microRNAs as biomarkers for tissue identification to distinguish between HCC and metastatic tumors in the liver.
Publication only abstracts:
5. "MicroRNAs as specific biomarkers for distinguishin
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved